i3 Announces Global Expansion

Pharmaceutical services company i3 has entered the next phase of its global expansion which includes organic and acquired growth in India, Latin America and Europe.

Coupled with acquisitions in Canada and Asia Pacific that i3 made earlier this year, the additions will help i3’s pharmaceutical clients bring high-quality, well-tested drugs to market faster and cheaper.

i3’s Latin American expansion is due to its acquisition of one of the region’s largest privately held contract research organizations, which has operations in Argentina, Brazil, Costa Rica, Mexico, Peru and Uruguay. Its expansion in India includes the opening of a full service office in Delhi, which will provide clinical research and data services for India-specific and global drug trials. New offices in Poland and expanded offices in France and the United Kingdom will boost the company’s European presence.

“Our strategy of increased geographic reach continues to honor i3’s responsibility to our customers,” says Glenn Bilawsky, i3’s CEO. “Pharmaceutical companies want to expedite development and gain cost efficiencies through well-run trials that are completed on time and on budget. Our expansion will help us accomplish those goals while still maintaining i3’s commitment to specialization and quality, which has become an industry hallmark.”

For more information, visit www.i3global.com/en/press/Press_release_i3globalexpansion.pdf.

About The Author